A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Olaratumab (Primary) ; Doxorubicin; Ifosfamide; Irinotecan; Vincristine
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 04 Apr 2018 Planned number of patients changed from 70 to 79.
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 30 Aug 2016 Status changed from not yet recruiting to recruiting.